Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Nov 23;4(11):e7954.
doi: 10.1371/journal.pone.0007954.

Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis

Affiliations

Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis

Francine Matthys et al. PLoS One. .

Abstract

Standard short course chemotherapy is recommended by the World Health Organization to control tuberculosis worldwide. However, in settings with high drug resistance, first line standard regimens are linked with high treatment failure. We evaluated treatment outcomes after standardized chemotherapy with the WHO recommended category II retreatment regimen in a prison with a high prevalence of drug resistant tuberculosis (TB). A cohort of 233 culture positive TB patients was followed through smear microscopy, culture, drug susceptibility testing and DNA fingerprinting at baseline, after 3 months and at the end of treatment. Overall 172 patients (74%) became culture negative, while 43 (18%) remained positive at the end of treatment. Among those 43 cases, 58% of failures were determined to be due to treatment with an inadequate drug regimen and 42% to either an initial mixed infection or re-infection while under treatment. Overall, drug resistance amplification during treatment occurred in 3.4% of the patient cohort. This study demonstrates that treatment failure is linked to initial drug resistance, that amplification of drug resistance occurs, and that mixed infection and re-infection during standard treatment contribute to treatment failure in confined settings with high prevalence of drug resistance.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Similar articles

Cited by

References

    1. Shilova MV, Dye C. The resurge of tuberculosis in Russia. Phil Trans R Soc Lond B Biol Sci. 2001;356:1069–1075. - PMC - PubMed
    1. Perelman MI. Tuberculosis in Russia. Int J Tuberc Lung Dis. 2000;4:1097–1103. - PubMed
    1. World Health Organisation. WHO tuberculosis programme. Framework for effective tuberculosis control. 1994. WHO/TB/94.179. Geneva, Switserland.
    1. Pablos-Méndez A, Raviglione M, Laszlo A, Binkin N, Rieder H, et al. Global surveillance for antitiuberculosis drug resistnnce 1994-1997. N Engl J Med. 1998;338:1641–1649. - PubMed
    1. World Health Organization. 2008. Anti-tuberculosis Drug Resistance in the World. Report n° 4. WHO/HTM/TB/2008.394. Geneva, Switserland.

Substances